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Background:We aimed to assess efficacy and safety of anti-tumor necrosis factor (TNF)
drugs for adult chronic non-infectious uveitis (NIU).
Methods: CENTRAL, MEDLINE, and EMBASE, were searched from inception to
January 2019. Double-masked randomized placebo-controlled trials, assessing any
anti-TNF vs. best medical intervention/standard of care in adults with chronic NIU
were considered. The PRISMA and SAMPL guidelines were followed. The risk of bias
was assessed using the Cochrane risk of bias tool. Overall quality of the evidence
was assessed according to GRADE. PROSPERO registration: #CRD42016039068.
The primary efficacy and safety outcomes were preservation of visual acuity (VA) and
withdrawals due to adverse events, respectively. Meta-analysis of efficacy analysis was
not performed due to significant clinical heterogeneity between studies’ population
and interventions.
Results: A total of 1,157 references were considered and 3 studies were included.
The overall risk of bias was moderate. In active NIU, adalimumab group showed an
increased likelihood of VA preservation (risk ratio (RR) 1.75, 95%CI 1.32 to 2.32, n
= 217), whereas the etanercept group did not (RR 0.81, 95%CI 0.57 to 1.14, n
= 20). In inactive NIU, adalimumab was associated with increased likelihood of VA
preservation (RR 1.31, 95%CI 1.12 to 1.53, n = 226). The rate of adverse events did
not differ between anti-TNF and control arms (RR 1.03, 95%CI 0.94 to 1.13, n = 410).
Leal et al. Anti-TNF Drugs for Chronic Uveitis in Adults
Conclusions: There is high quality evidence that adalimumab decreases the risk of
worsening VA in active and inactive NIU and very low quality evidence that the risk of
etanercept worsening VA in inactive NIU is not different from placebo. Moderate quality
evidence suggests that anti-TNF agents are not different from placebo on the risk of
study withdrawal.
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INTRODUCTION
Rationale
Uveitis comprises a heterogeneous group of inflammatory
diseases of the uvea of both infectious and non-infectious
etiologies. Specifically, non-infectious uveitis (NIU) is thought
to result from an immune-mediated response to ocular antigens
(1, 2). Given its estimated incidence (52/100 000 person-years)
and reported prevalence (115–121/100,000 people) (3, 4) NIU
brings with it significant burden for the healthcare systems and
in this working age group (2, 5). Complications of uveitis can be
sight threatening, severely impairing quality of life (1, 6).
The therapeutic goal for NIU is to reduce ocular
inflammation, thus preventing damage to ocular structures
and consequent vision loss. Corticosteroids are the mainstay
of therapy, however, these drugs are often incapable of proper
inflammation control and have long-term systemic side effects
(7, 8). When inflammation is not controlled by corticosteroids or
side effects are intolerable, systemic immunomodulatory therapy
(IMT) should be considered (5, 9). Current IMT includes the
inhibition of TNF, achieved with mAb, such as infliximab,
adalimumab, golimumab, and certolizumab-pegol, or with
receptor fusion protein (FP), etanercept (9, 10).
Although anti-TNF drugs are approved for many other
chronic immune-mediated inflammatory diseases, they are still
used off-label for NIU, with the exception of adalimumab that
has recently been approved for this indication (8, 11).
Objective and Research Question
We conducted a systematic review with meta-analysis of
randomized controlled trials (RCT) to summarize the available
evidence, to grade the quality of the available studies, to mark
out areas of intellectual disagreement, and to draw attention to
matters to all stakeholders requiring future development.
METHODS
Study Design
For a detailed description of the methods, please refer to
Appendix 1.
Systematic Review Protocol
The protocol followed the PRISMA-P guidelines (12) and it was
registered at Prospero database (CRD42016039068). Reporting
followed the PRISMA and SAMPL guidelines (13, 14).
Participants, Interventions, Comparators
We analyzed parallel RCT of any duration, assessing efficacy
and safety of anti-TNF vs. control interventions in patients with
chronic NIU. RCT had to include adult patients with a clinical
diagnosis of chronic NIU, irrespective of the etiology.
Search Strategy
For the identification of studies considered for inclusion in
this review, detailed search strategies were developed for
each database explored. Please refer to Appendices 2–4 for
the MEDLINE, EMBASE and CENTRAL search strategies,
respectively. The search strategies for the other databases can be
found in Appendices 5–8.
Data Sources, Studies Sections, and Data
Extraction
We searched MEDLINE, EMBASE, CENTRAL,
OpenSIGLE.inist.fr, NTIS.gov, ClinicalTrials.gov, and
ClinicalTrialsRegistry.eu. Gray literature was retrieved from
appropriate databases. Clinical trials registries were pursued.
Whenever necessary, authors of published trials were contacted
for further information and unpublished data. Search strategies
were designed, tested and applied to databases by one of the
authors (FR).
Study Selection
Independent review authors assessed if the studies identified
by the search strategy were eligible. The same authors
independently screened the full-texts of potentially eligible
studies. Disagreements were resolved by consensus, or with the
participation of a third author.
Data Analysis
Data Collection Process
Two authors independently assessed the full-text articles
of included studies for methodological quality and data
extraction, then extracted the data onto standardized forms and
crosschecked them for accuracy. Disagreements were resolved
by discussion, and consensus was reached with participation of
three authors.
Risk of Bias in Individual Studies
The recommended Cochrane Collaboration’s tool for assessing
risk of bias was used in this review, which targets six specific risk
of bias domains (15). Two additional domains were added: for-
profit bias, and prospective trial registration. Two independent
review authors performed critical assessments for each domain.
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Disagreements were resolved by discussion and, if needed,
consensus was reached with the participation of a third author.
Summary Measures
The primary efficacy outcome was preservation of best-corrected
visual acuity (VA), in logMAR, measured and presented
according to the standard procedure developed for the Early
Treatment Diabetic Retinopathy Study (16) in the end of
the study.
The primary safety outcome was withdrawals due to
adverse events.
The secondary efficacy outcomes were: change from baseline
in anterior chamber and/or vitreous inflammation grade and
(according to Standardization of Uveitis Nomenclature (SUN)
(17, 18) recorder in the last measurement. In case one eye
improved but the other eye deteriorate, we considered the
changes from baseline in anterior chamber and/or vitreous
inflammation reported in the worsening eye; other secondary
outcomes were median time to Optical Coherence Tomography
(OCT), evidence of cystoidmacular oedema (CME), change from
baseline in the score after 16–20 weeks of therapy obtained in
a vision-specific questionnaire, the National Eye Institute Visual
Functioning Questionnaire 25 (NEI-VFQ) (19).
The secondary safety outcomes were number of patients with:
(i) infections, (ii) new onset or reactivated tuberculosis, (iii)
injection site or allergic reactions, (iv) immunogenicity related
adverse events, and (v) other adverse events.
For dichotomous outcomes, we retrieved the total number of
included patients for each arm (i.e., anti-TNF and control), and
the number experiencing the outcome. We reported numerators
and denominators for all percentages. For continuous outcomes,
we retrieved the mean or median—the latter converted to mean
using statistically validated methods (20). We reported means
and standard deviations (SD). For counts, we reported the mean
per participant and SD as presented by the authors. We carried
an intention-to-treat analysis using risk ratios for dichotomous
outcomes, mean differences for continuous outcomes, and rates
and SD for counts. The proportion of patients with adverse events
was compared between treatment arms, and further analysis was
performed in the most frequent complications reported in trials.
Data was pooled from the studies where adequate, and used
for comparison.
Synthesis of Results
Statistical analysis was performed with Review Manager v 5.3.
Dichotomous data were preferentially reported in this review as
risk ratios using a Mantel-Haenszel fixed-effects (FE) model and
95% confidence intervals (95% CI). Continuous outcomes, such
as efficacy measures, were reported as mean differences and 95%
CI. For counts, the rate ratios were pooled using the generic
inverse-variance method. Where data from the studies reports
could not be combined into a meta-analysis, a narrative approach
to synthesis of the results was included in the review text.
Heterogeneity between trial results was tested using an
I2 statistic to quantify inconsistency across studies. When
considerable heterogeneity was present (i.e., I2 > 50%), the
possible causes of heterogeneity were explored by conducting
subgroup analysis. Where heterogeneity could not readily
be explained by the exploratory analyses performed, it was
incorporated into a Random-Effects (RE) meta-analysis model.
Risk of Bias Across Studies
Publication bias was planned to be assessed through visual
inspection of funnel plots asymmetry and Peters’ regression tests
(21, 22), if more than 10 studies per outcome were available
(15). Unfortunately we did not have enough power to perform
these analyses.
Additional Analysis
Subgroup analysis was pre-planned for the following: uveitis
etiology (primary vs. secondary; different secondary causes),
risk of bias, pharmacological compound (infliximab vs.
adalimumab vs. certolizumab vs. golimumab vs. etanercept),
age of participants, mean follow-up time, steroid-resistant or
dependent, and BCVA (15). Unfortunately, we did not have
enough power to perform these analyses.
Confidence in Cumulative Evidence
All primary outcomes were evaluated according to quality of
evidence using the GRADE working group methodology (23).
Secondary safety outcomes and the proportion of patients
achieving an excellent functional outcome at 90 days after
randomization were also graded.
RESULTS
Study Selection and Characteristics
Study Selection
A total of 1,233 references were identified (MEDLINE: 1052;
Embase: 137; CENTRAL: 44) (Figure 1). No additional records
were identified through other sources or manual search. After
duplicates removal, 1,157 papers were screened for title and
abstract and 20 references were examined in full-text. Of these,
17 studies were excluded, 5 due to study design and 12 due to
wrong patient population. Three studies were included in the
final analysis: Foster et al. (24) and VISUAL I and II (25, 26).
Study Characteristics
Of the three studies included in our analysis, VISUAL I (25) and
VISUAL II (26) assessed efficacy and safety of adalimumab in
controlling inflammation in active uveitis and preventing uveitic
flare in inactive uveitis, respectively, and the other study [hereby
defined as Foster et al. (24)] assessed the efficacy and safety of
etanercept in preventing flare of uveitis previously controlled
with methotrexate. All studies compared placebo and anti-TNF
between arms. VISUAL I enrolled 217 patients, VISUAL II
enrolled 226 patients and Foster et al. (24) enrolled 20 patients.
Overall, the studies involved 458 participants−230 in the anti-
TNF arm and 228 in the control arm, based on an intention-
to-treat population. VISUAL I included adult patients with a
diagnose of active non-infectious intermediate uveitis, posterior
uveitis or panuveitis despite the use of prednisone (10 to 60
mg/day) or an equivalent corticosteroid for 2 or more weeks
before screening; VISUAL II included adult patients with a
diagnosis of inactive non-infectious intermediate, posterior or
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FIGURE 1 | Flow diagram.
panuveitis for at least 28 days before the baseline visit, and use
of 10–35 mg/day of oral prednisone to maintain inactive disease;
finally, in Foster et al. (24), eligible participants were adult
patients treated for recurrent uveitis and taking methotrexate
(≤15mg/kg per week) for at least 12 weeks with control of uveitis.
Main study characteristics are depicted in Table 1.
Randomization was stratified by baseline immunosuppressant
treatment in VISUAL I and VISUAL II, but not in Foster et al.
(24). Intention-to-treat analysis was used in all three studies to
evaluate efficacy endpoints.
Mean age ranged from 42 to 48 years and sex distribution
favored female in all three studies (Supplementary Table 1).
However, in VISUAL I, sex distribution was not disclosed
between arms. Supplementary Table 1 summarizes population
baseline characteristics by individual study.
Synthesized Findings
Table 2 summarizes the results of individual studies.
In VISUAL I, adalimumab was efficacious, as the risk ratio of
not worsening BCVAwas 1.75 (95%CI 1.32 to 2.32) comparing to
placebo. Moreover, the results favored adalimumab for change in
anterior chamber [mean difference between groups: −0.29 (95%
CI −0.51 to −0.07)] and vitreous inflammation grades [mean
difference:−0.27 (95%CI−0.43 to−0.11)], median time to OCT
evidence of CME (placebo arm: 6,2 months, anti-TNF arm: 11,1
months) and change in VFQ-25 (27) composite score (placebo
arm:−5.5; anti-TNF arm:−1.3).
In VISUAL II, adalimumab was efficacious, as the risk ratio
for not worsening BCVA was 1.31 (95% CI 1.12 to 1.53)
vs. placebo. The results for other efficacy outcomes were not
different between groups: change in anterior chamber [mean
difference: −0.14 (95% CI −0.37 to 0.08], vitreous inflammation
[mean difference: −0.13 (95% CI −0.28 to 0.01)] grades and
change in VFQ-25 composite score (placebo arm: 1.24; anti-
TNF arm: 3.36). The median time to OCT evidence of CME was
not estimable.
In Foster et al. (24), etanercept was not associated with a risk
reduction of not worsening BCVA comparing to placebo (risk
ratio 0.90, 95% CI 0.69 to 1.18).
Synthesis of Results
Efficacy
In our view, there is significant clinical heterogeneity between
studies’ population and intervention. Therefore, we decided not
to pool the 3 studies together for efficacy analysis, as the pooled
analysis would not lead to a meaningful conclusion. Results of
individual studies were incorporated in Table 2 and have been
described above.
Safety
However, for safety outcomes, as all studies used anti-TNF drugs
as active intervention and safety outcomes analyzed are specific
to this drug class, we decided to pool and quantitatively assess
them (28). The rate of adverse events in VISUAL I and II trials
did not differ between the anti-TNF and control arms (rate ratio
1.03, 95% CI 0.92 to 1.14, n= 443, I2 = 65%; Figure 2A), nor did
that of serious adverse events (rate ratio 1.47, 95% CI 0.69 to 3.13,
n= 443, I2 = 58%; Figure 2B and Table 3).
Regarding safety outcomes, withdrawals were pooled together
for the three studies, and there were no differences in the
risk of withdrawing in the anti-TNF arm group comparing to
placebo (risk ratio 1.63, 95% CI 0.62 to 4.26, n = 472, I2
= 59%) (Figure 2C). Some other safety outcomes were only
pooled together for both VISUAL studies due to absence of
correspondent information in Foster et al. (24). In both VISUAL
studies, the results (Table 3) significantly favored placebo for
injection site-events (rate ratio: 2.16, 95%CI 1.2 to 3.60, n =
443) and number of patients with anti-drug antibodies (risk ratio:
10.38, 95%CI 1.34 to 80.69, n = 443). There were no differences
in rate or risk ratios for the other analyzed endpoints between
adalimumab and placebo arms. In Foster et al. (24), the results
for the risk of patients experiencing adverse effects were also not
different (risk ratio 1.50, 95% CI 0.60 to 3.74, n= 20).
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TABLE 2 | Efficacy and Safety results by individual study.
Foster VISUAL I VISUAL II
Anti-TNF Placebo Anti-TNF Placebo Anti-TNF Placebo
Risk of not worsening BCVA risk ratio (95% CI) 0.90 (0.69−1.18) 1.75 (1.32, 2.32) 1.31 (1.12, 1.53)
Mean change in anterior chamber cell grade MD (95%CI) N.S. −0.29 (−0.51, −0.07) −0.14 (−0.37, 0.08)
Mean change in vitreous haze grade (mean between group difference, 95%CI) N.S. −0.27 (−0.43, −0.11) −0.13 (−0.28, 0.01)
Median time to OCT evidence of CME on or after week 6 (months) N.S. 11.1a 6.2b N.S.
Change in VFQ-25 total score N.S. 4.20 (1.02, 7.38) 2.12 (−0.84, 5.08)
Serious infections (rate ratio and 95%CI) N.S. 1.18 (0.42, 3.27) 1.14 (0.23, 5.68)
TB (active and latent) (risk ratio and 95% CI) N.S. 5.04 (0.24, 103.90) 2.97 (0.31, 28.17)
Injection-site events (rate ratio and 95%CI) N.S. 2.84 (1.60, 5.05) 1.69 (1.00, 2.84)
Number of patients with anti-drug antibodies (risk ratio and 95% CI) N.S. 7.06 (0.37, 135.16) 14.87 (0.86, 257)
Allergic adverse events (rate ratio and 95%CI) N.S. 1.65 (0.84, 3.23) 0.47 (0.17, 1.31)
Adverse events (rate ratio and 95%CI) 1.50 (0.60, 3.74)c 1.08 (0.99, 1.18) 0.97 (0.89, 1.06)
Serious adverse events (rate ratio and 95%CI) N.S. 2.12 (1.11, 4.04) 0.98 (0.47, 2.06)
Adverse events leading to death (rate ratio and 95%CI) 1.00 (0.02, 46.05)c 3.20 (0.13, 76,58) 4.20 (0.19, 91.13)
Events of lupus or lupus-like events (rate ratio and 95%CI) N.S. 3.00 (0.12, 73.21) 1.00 (0.02, 50.40)
Events of demyelination (rate ratio and 95%CI) N.S. 3.00 (0.12, 73.21) 1.00 (0.02, 50.40)
Events of cancer (rate ratio and 95%CI) N.S. 6.40 (0.33, 125.89) 2.20 (0.08–62.81)
Total number of withdrawals (risk ratio and 95% CI) 5.00 (0.27, 92.62) 2.59 (1.13, 5.97) 0.87 (0.44, 1.69)
Withdrawals due to adverse events (risk ratio and 95% CI) 5.00 (0.27, 92.62) 3.36 (0.95, 11.90) 1.42 (0.56, 3.59)
Withdrawals due to lost to follow-up (risk ratio and 95% CI) 1.00 (0.02, 46.05) 9.08 (0.49, 166.69) 0.14 (0.01, 2.71)
Withdrawals by patient (risk ratio and 95% CI) 1.00 (0.02, 46.05) 5.04 (0.24, 103.90) 0.66 (0.11, 3.88)
Withdrawals for other reasons (risk ratio and 95% CI) 1.00 (0.02, 46.05) 1.68 (0.41, 6.87) 0.66 (0.11, 3.88)
Withdrawal due to lack of efficacy (risk ratio and 95% CI) 1.00 (0.02, 46.05) 0.50 (0.05, 5.48) 0.14 (0.01, 2.71)
BCVA, best corrected visual acuity; CI, confidence interval; TNF, tumor necrosis factor; N.S., non-stated; OCT, optical coherence tomography; CME, cystoid macular edema; VFQ,
visual function questionnaire; TB, tuberculosis; MD, mean difference.
aevaluated in 55 patients (CME was included only for patients who did not have CME at baseline).
bevaluated in 45 patients (CME was included only for patients who did not have CME at baseline).
ccalculated as risk ratio.
Risk of Bias
The overall risk of bias was moderate.
Incomplete outcome data (attrition bias) was the only item
considered of low risk across all studies (Figure 3). In fact, in
VISUAL I and II, missing outcome data is balanced in numbers
across intervention groups and in Foster et al. (24) there is no
missing data.
In VISUAL I and II, random sequence generation was
considered of low risk because the investigators describe a
random component in the sequence generation; allocation
concealment (selection bias) was considered of low risk,
since there was a computer-generated assignment sequence
of allocation; blinding of participants, personnel and outcome
assessors were also of low risk because measures to blind
participants, personnel and outcome assessors from knowledge
of which intervention a participant received are described;
as study protocols are available and all studies’ pre-specified
outcomes were reported in the studies’ main paper or in available
Supplementary Files, selective reporting were considered of
low-risk. Prospective trial registration was accomplished in
both studies.
No available information was found regarding random
sequence generation, allocation concealment (selection bias),
blinding of participants and personnel or blinding outcome
assessment in Foster et al. (24) and, therefore, these items were
considered of unclear risk. Due to the lack of outcomes reported
in ocular inflammation studies (change in BCVA in logMar,
anterior chamber and vitreous inflammation grade) and lack of
available protocol, selective reporting was considered of high risk
in Foster et al. (24). Prospective clinical trials registration was not
available in Foster et al. (24).
VISUAL I and II were industry-funded and in Foster et al.
(24) the sponsor provided placebo and the active comparator;
for these reasons, for-profit bias was considered of high risk
across studies.
Risk of Bias Across Studies
Not performed due to lack information.
Additional Analysis
Not performed due to lack information.
DISCUSSION
Summary of Main Findings
According with the GRADE, there is very low quality evidence
that the risk of etanercept not worsening visual acuity in inactive
NIU is not different from placebo, and high quality evidence
Frontiers in Medicine | www.frontiersin.org 6 May 2019 | Volume 6 | Article 104
Leal et al. Anti-TNF Drugs for Chronic Uveitis in Adults
FIGURE 2 | Forest plot. (A) Rate of adverse events between the anti-TNF and control arms. (B) Rate of serious adverse events between the anti-TNF and control
arms. (C) Risk of withdrawing between the anti-TNF and control arms.
that adalimumab increases this risk of not worsening visual
acuity in active and inactive NIU. Furthermore, moderate quality
evidence suggests that anti-TNF agents are not different from
placebo on the risk of trial withdrawal (Supplementary Table 2).
These conclusions are based on 2 randomized controlled trials
enrolling 443 patients with active and inactive NIU, comparing
adalimumab with placebo. Another small study with 20 patients
with controlled NIU, failed to show a positive effect of etanercept
vs. placebo in preventing uveitis flare.
Clinical, methodological and design heterogeneity between
studies precluded a pooled analysis of efficacy outcomes.
However, for safety, as we analyzed drug class-related adverse
events common to all anti-TNF drugs, the results were pooled
and the risk of adverse events did not differ between the anti-TNF
and control arms. Of note, included studies were not adequately
powered to study adverse events.
The use of two different drugs in the active arm [etanercept
in Foster et al. (24) and adalimumab in VISUAL I and VISUAL
II] and important disparities regarding the number of patients
randomized [217 in VISUAL I, 226 in VISUAL II and 20 in
Foster et al. (24)] are probably pivotal factors that explain the
difference between risk of not worsening BCVA with anti-TNF
and placebo in the different studies. Thus, results of this specific
endpoint favored adalimumab over placebo in both VISUAL
studies and suggested a worse efficacy profile in the etanercept
over placebo, although this result was not statistically significant.
Moreover, regarding population disparities, both VISUAL I and
II focused ocular inflammation in the intermediate or posterior
eye compartments or affecting the three eye compartments
(panuveitis), whereas Foster et al. (24) included patients whose
etiology of uveitis is more closely linked to anterior inflammatory
processes (although the affected eye compartments is an item
not specified in the study), such as HLA-B27-associated uveitis
and arthritis-associated uveitis (29). It should be emphasized
that Foster et al. (24) is a much less robust trial than the two
VISUAL studies.
Adalimumab is a fully human-derived monoclonal antibody,
produced by recombinant DNA technology. It binds to human
TNF with high affinity and specificity, and blocks TNF pathway
via interaction with p55 and p75 cell-surface TNF receptors
(11, 30). Before these two studies with adalimumab, there was
evidence of its efficacy and safety in adult NIU from case reports
with adalimumab (31, 32), case series with adalimumab given
for ocular disease (33–35), case series with adalimumab given
for other rheumatic conditions (36), and prospective open-
label trials (37–40). The cumulative evidence in literature of
the effectiveness and safety of adalimumab in NIU together
with its high specificity for TNF are in line with the favorable
results observed in both VISUAL-I and II (41). These are well-
designed multi-centric double-masked randomized trials that
provide high-quality evidence for the use of adalimumab in active
and non-inactive NIU. It should be noted though, that both
of these studies excluded anterior NIU, for which high quality
evidence is still lacking (42).
On the other hand, etanercept is a humanized, recombinant
fusion protein, consisting of the p75 TNF receptor II, combined
with the Fc tail domain of the human immunoglobulin (IgG)
1. This fusion protein blocks the interaction of TNF with cell
Frontiers in Medicine | www.frontiersin.org 7 May 2019 | Volume 6 | Article 104
Leal et al. Anti-TNF Drugs for Chronic Uveitis in Adults
TABLE 3 | Safety results meta-analysis.
Anti-TNF vs. Placebo
Foster VISUAL I VISUAL II
Serious infections (rate ratio and 95%CI) N.S. 1.17 (0.49, 2.76)
TB (active and latent) (risk ratio and 95% CI) N.S. 3.59 (0.59, 21.81)
Injection-site events (rate ratio and 95%CI) N.S. 2.16 (1.29, 3.60)
Number of patients with anti-drug antibodies (risk ratio and 95% CI) N.S. 10.38 (1.34, 80.69)
Allergic adverse events (rate ratio and 95%CI) N.S. 0.94 (0.28, 3.19)
Adverse events (rate ratio and 95%CI) 1.50 (0.60, 3.74)a 1.02 (0.92, 1.14)
Serious adverse events (rate ratio and 95%CI) N.S. 1.47 (0.69, 3.13)
Adverse events leading to death (rate ratio and 95%CI) 1.00 (0.02, 46.05)a 3.68 (0.40, 33.55)
Events of lupus or lupus-like events (rate ratio and 95%CI) N.S. 1.94 (0.16, 23.02)
Events of demyelination (rate ratio and 95%CI) N.S. 1.94 (0.16, 23.02)
Events of cancer (rate ratio and 95%CI) N.S. 3.99 (0.43, 37.03)
Total number of withdrawals (risk ratio and 95% CI) 1.63 (0.62, 4.26)
Withdrawals due to adverse events (risk ratio and 95% CI) 2.04 (0.99, 4.21)
Withdrawals due to lost to follow-up (risk ratio and 95% CI) 1.00 (0.02, 46.05) 1.14 (0.02, 67.56)
Withdrawals by patient (risk ratio and 95% CI) 1.00 (0.02, 46.05) 1.25 (0.19, 8.18)
Withdrawals for other reasons (risk ratio and 95% CI) 1.00 (0.02, 46.05) 1.17 (0.39, 3.52)
Withdrawal due to lack of efficacy (risk ratio and 95% CI) 1.00 (0.02, 46.05) 0.31 (0.05, 1.95)
BCVA, best corrected visual acuity; CI, confidence interval; TNF, tumor necrosis factor; N.S., non-available; OCT, optical coherence tomography; CME, cystoid macular edema; VFQ,
visual function questionnaire; TB, tuberculosis; acalculated as risk ratio.
FIGURE 3 | Risk of bias summary.
surface TNF receptors (11). Initial studies suggested encouraging
results for etanercept in ocular inflammation control (43).
However, long term non-RCT follow-up studies and more recent
studies proposed clear inferiority in ocular inflammation control
compared to other anti-TNF, such as infliximab or adalimumab
(44, 45). Furthermore, some authors also suggest that etanercept
may have immunodysregulatory and even pro-inflammatory
effects, triggering uveitis (39, 46, 47). The pathophysiology of
this phenomenon is still ill-defined (48, 49). The only study
included using etanercept suggested a decreased likelihood of
VA preservation comparing to placebo, although not significant.
Foster et al. (24)’s small sample size could have also contributed to
the mentioned efficacy result. Another possible reason for these
results could be the poor effect of etanercept in protecting against
uveitis. It should be emphasized that Foster et al. published this
trial in 2003 and only a few years later there was increasing
evidence for the possible uveitis-inducing effect of this drug
(43). In general, this trial was much smaller than the trials
using adalimumab and the risk of bias was higher due to
methodological reasons. Therefore, caution must be taken when
considering its results.
Until now, only three RCT studying anti-TNF against
placebo in NIU have been published, one with etanercept
and two with adalimumab. Only one among the three
available RCT was performed on patients with active NIU.
The total number of patients so far treated with etanercept
is too small for us to be confident to draw conclusions of
its efficacy.
A next step for future trials would be the comparison
vs. placebo of other anti-TNF drugs that are not approved
for NIU management but are commonly used off-label, such
as infliximab, or the comparison of anti-TNF drugs against
conventional immunosupressors widely used in NIU. Also,
considering trials evaluating not only the capability of anti-TNF
to induce remission of the inflammatory process in patients
with active NIU, but also assessing the capability of anti-TNF
to prevent uveitic flare in patients with inactive NIU would be
of paramount importance. Finally, given the limited number
of RCT, the inclusion of observational studies would be a
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convenient approach to further study the safety and efficacy
profile of these drugs in NIU.
Limitations
Although study design across studies is identical (RCT
evaluation anti-TNF vs. placebo in NIU), population and
active interventions are not comparable across studies. The
three studies have diverse methods, using distinctive drugs as
active arm and report on widely different populations, which
compromises data aggregation in the pooled-analysis for safety
outcomes and efficacy comparisons. Secondly, although our
initial aim was to evaluate efficacy and safety of anti-TNF in NIU,
only two of five commercially available anti-TNF drugs were used
in these three studies. Thirdly, the 2 largest trials included in this
work have both been funded by the adalimumab drug company,
which may introduce bias in the study design, data collection,
data analysis and interpretation. We think that independent
(academic and/or investigator-initiated) trials are required with
longer follow-up to be able to draw more solid conclusions.
It should be noted the limited generalizability of RCT when
it comes to safety analysis. Because populations are generally
not very big, follow-up times are not long enough to identify
rare adverse effects and patients with high risk of adverse effects
are often excluded, RCT are not the best tools to study safety
outcomes. This should be taken into account when interpreting
our safety analysis (50). Additionally, profit bias was considered
of high risk across studies. Despite these limitations, we believe
that our work aggregates the currently best available evidence
regarding the use of anti-TNF vs. placebo in NIU.
CONCLUSIONS
According with our predefined outcomes, adalimumab seems
efficacious for the treatment of active non-anterior NIU and
in preventing flare-ups from inactive non-anterior NIU; and
that adalimumab and etanercept are safe in people with NIU.
Overall, the evidence is not sufficiently robust to determine
the comparative effectiveness of anti-TNF in NIU. Our work
highlights the scarce evidence in the field and the need for future
robust trials to conclude about efficacy and safety of anti-TNF
drugs in NIU
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